Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24256612 | 0.88 | MTOR (0.60) | MTORSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24256357 | 0.88 | MTOR (0.53) | MTORSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24256709 | 0.87 | MTOR (0.61) | MTORSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24256707 | 0.82 | MTOR (0.58) | MTORSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24256858 | 0.77 | MTOR (0.63) | MTORSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24256362 | 0.75 | HPGD (0.52) | MTORSMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL24256358 | 0.75 | KDM4E (0.52) | MTORSMN1; SMN2ALDH1A1GAALMNA | |
| SCHEMBL24256672 | 0.75 | KMT2A (0.51) | SMN1; SMN2ALDH1A1GAAKMT2ANAMPT | |
| SCHEMBL26780707 | 0.74 | KDM4E (0.51) | MTORALDH1A1GAALMNAHPGD | |
| SCHEMBL24256678 | 0.74 | LMNA (0.67) | MTORSMN1; SMN2ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022035806-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365583-A1 | FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP30, USP8 | MTOR 2191/4885SMN1; SMN2 1921/4885ALDH1A1 1934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.